Insmed (INSM) Tops Q1 EPS by 17c ; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Insmed (INSM) PT Raised to $43 at Morgan Stanley
May 9, 2024 12:11 PM EDTMorgan Stanley analyst Jeffrey Hung raised the price target on Insmed (NASDAQ: INSM) to $43.00 (from $40.00) while maintaining a Overweight rating.
The analyst comments "Insmed reported 1Q Arikayce sales of $75.5M (consensus: $78M) and reiterated guidance 2024 Arikayce revenue guidance of $340M-360M. The company... More
